The United States CRISPR market is projected to reach $8.59 billion by 2033, growing at a CAGR of 16.6%. North America currently leads the global market, accounting for 48% of total revenue.

The Global CRISPR market reached US$ 3.93 billion in 2024 and is expected to reach US$ 15.25 billion by 2033, growing at a CAGR of 16.8% during the forecast period 2025-2033.

Download your exclusive sample report today: (corporate email gets priority access):https://www.datamintelligence.com/download-sample/crispr-market?pratik

The CRISPR market is growing due to rising demand for precise gene-editing tools, increasing investments in genetic research, and expanding applications in therapeutics, agriculture, and diagnostics. Advances in CRISPR-based drug development and supportive regulatory pathways further accelerate global adoption.

United States industry development
✅ The U.S. CRISPR and Cas genes market was valued at $2.16 billion in 2024 and is expected to grow at a compound annual growth rate (CAGR) of 16.6% from 2024 to 2033, reaching $8.59 billion by 2033.

✅ June 2025: Eli Lilly and Company agreed to acquire Verve Therapeutics a CRISPR / base-editing biotech for up to US $1.3 billion (US $1 billion upfront + US $300 million contingent on clinical milestones). This signals major pharma confidence in one-time, CRISPR-based therapies for chronic conditions like cardiovascular disease.

✅ 2025 (early / mid-year): CRISPR Therapeutics one of the leading CRISPR-Cas9 therapy developers continues advancing its in-vivo and ex-vivo gene-editing pipeline. As of March 31, 2025 the company reported holding US $1.86 billion in cash, cash equivalents and marketable securities, providing a substantial financial runway for ongoing trials.

✅ September 2025: CRISPR Therapeutics advanced its gene-editing pipeline with a focus on oncology and rare genetic disorders.

✅ August 2025: Editas Medicine announced promising clinical trial data for CRISPR-based treatments targeting inherited blood diseases.

✅ July 2025: Intellia Therapeutics secured FDA clearance for a CRISPR-Cas9 trial in metabolic disorders.

✅ July 2025: Prime Medicine received an additional investment of up to $24 million from the Cystic Fibrosis Foundation to advance gene editing therapy targeting cystic fibrosis.

✅ June 2025: Beam Therapeutics expanded base-editing research collaborations with U.S. biotech firms.

✅ May 2025: Verve Therapeutics progressed with in vivo CRISPR therapies aimed at cardiovascular diseases.

Global industry development
✅ October 2025: Algen Biotechnologies based in the U.S. (but significant globally) signed a licensing deal valued up to US $555 million with AstraZeneca to develop AI-driven, CRISPR-informed gene therapies for immune-system-related diseases, underscoring growing large-pharma investment into CRISPR-enabled drug development.

✅ 2025 (recent startup funding): Cassidy Bio a newer company focused on AI-driven genomic modeling to support safer and more scalable gene editing therapies closed an US $8 million seed financing round to build out its platform. The move exemplifies continuing venture-capital interest in CRISPR-adjacent innovation beyond just clinical-stage players.

✅ September 2025: The European Medicines Agency (EMA) fast-tracked the review of a CRISPR-based sickle cell therapy, reflecting global regulatory interest and acceleration.

✅ Various dates in 2025: Increasing global investments in CRISPR research and clinical trials, with the market expected to grow strongly driven by advances in genomic medicine and gene therapies.

Recent Merges & acquisition
→ June 2025: Eli Lilly & Co. announced it will acquire Verve Therapeutics in a deal valued at up to US $1.3 billion, expanding Lilly's gene-editing and cardiovascular therapy capabilities.

→ July 2025: Funding group managed by Perceptive Advisors acquired Synthego, a CRISPR reagent and gene-editing tools provider boosting Synthego's capacity to support global therapeutic R&D.

→ November 2025: ToolGen entered a strategic cross-license agreement with GenEditBio to combine ToolGen's CRISPR-Cas9 platform with GenEditBio's lipid nanoparticle delivery technology strengthening in vivo gene-editing therapy development.

Market Segmentation-

Segmentation by Offering
→ Products: This segment includes CRISPR kits, enzymes, libraries, and reagents used for gene editing in research, clinical, and industrial applications. It accounted for around 63% of the market share, driven by their essential role in accelerating genetic research and therapy development.

→ Services: This segment covers cell line engineering, gRNA design and vector consultation, screening services, and other custom gene-editing services. It represents about 38% of the market, with fast growth due to rising demand for outsourced precision gene-editing solutions by academic and biotech firms.

Segmentation by Application
→ Biomedical: This segment is the largest, focusing on gene therapy, drug discovery, functional genomics, and diagnostics, holding an estimated 57% market share. It benefits from high demand for CRISPR tools in cancer, rare disease research, and therapeutic development pipelines.

→ Agricultural: This segment includes crop improvement, food security, and sustainable agriculture applications. It holds around 17% of the market share, propelled by the need for enhanced crop resistance, shelf life, and nutritional value in response to climate change.

→ Industrial: Industrial biotechnology applications such as synthetic biology and microbial engineering for biodegradable plastics and carbon-negative microbes constitute roughly 14% of the market. This segment sees rising interest due to environmental mandates.

→ Other Applications: These include environmental research and less common uses, collectively representing about 10% of the market.

"Secure your 30% year-end discount - get this report before the offer expires."
:https://www.datamintelligence.com/buy-now-page?report=crispr-market?pratik ((Purchase 2 or more Repots and get 50% Discount)

Regional insights:-
→ North America leads the CRISPR market with 48% market share, driven by advanced biotechnology infrastructure, significant government and private funding, key market players, and supportive regulatory frameworks.

→ Europe, led by countries such as Germany, the UK, and France, is growing strongly supported by collaborations between universities, research institutions, biotech firms, and robust genomics infrastructure.

→ Asia Pacific shows rapid growth with China's significant market expansion due to strong government support, fast-tracked regulatory approvals, heavy R&D investments, and a large patient population. India is also showing steady growth due to biotech investments and applications in agriculture and medicine.

→ Canada has notable growth with increasing biotech research investments and innovation collaborations.

→ Germany specifically is highlighted for regional growth within Europe due to its biotech ecosystem and significant R&D investments.

Key Players
Thermo Fisher Scientific, Merck KGaA, Agilent Technologies, GenScript, Creative Biogene, Bio-Rad, QIAGEN, Takara Bio, Synthego, and Eurofins Genomics.

→ Thermo Fisher Scientific is a leading global player with a presence in more than 60 countries. It offers a diversified product portfolio that includes reagents, enzymes, kits, and services specifically for CRISPR applications. The company invests heavily in R&D, having invested USD 1.4 billion in 2024 to strengthen its global offerings. It has a strong presence in Europe, North America, and Asia-Pacific, focusing on delivering cutting-edge technologies for genome editing and research.​

→ Agilent Technologies is another major competitor with a global presence in over 30 countries. It specializes in CRISPR-related reagents, enzymes, and service kits like SureGuide Cas9 Nuclease Kits. Agilent's strengths lie in its broad portfolio and brand recognition, enabling it to support a wide range of applications from phenotypic screening to lead optimization.​

→ Merck KGaA (Germany) provides comprehensive health science solutions that extend from discovery to diagnosis. Its Life Sciences division offers various CRISPR tools and gene editing products supporting research in cell and gene studies. Merck's strong brand and extensive portfolio enhance its collaboration with clients worldwide, contributing to its top market position.​

Get Customization in the report as per your requirements:https://www.datamintelligence.com/customize/crispr-market?pratik

Market Drivers:-

Rising demand for CRISPR-based gene therapies addressing unmet medical needs, especially in cancer and rare genetic diseases.

High prevalence of genetic disorders increasing need for precise and efficient gene editing.

Advances in CRISPR technology enhancing accuracy, safety, and adaptability for personalized medicine.

Expanding applications in agriculture and livestock to improve crop yields, disease resistance, and sustainable farming.

Strong capital investments and growing partnerships between CRISPR providers and major pharmaceutical companies.

Supportive government funding, regulatory clarity, and intellectual property frameworks accelerating commercial adoption.

Request for 2 Days FREE Trial Access:
https://www.datamintelligence.com/reports-subscription?pratik
✅ Competitive Landscape
✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Consumer Behavior & Demand Analysis
✅ Import-Export Data Monitoring
✅ Live Market & Pricing Trends

Have a look at our Subscription Dashboard:
https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About DataM Intelligence
DataM Intelligence is a renowned provider of market research, delivering deep insightsthrough pricing analysis, market share breakdowns, and competitive intelligence. Thecompany specializes in strategic reports that guide businesses in high-growth sectors suchas nutraceuticals and AI-driven health innovations.
To find out more, visit https://www.datamintelligence.com/ or follow us on Twitter,LinkedIn and Facebook.

This release was published on openPR.